与阿尔茨海默病相关的补充基因变异影响了血补充蛋白水平
Aurora Veteleanu1, Joshua Stevenson-Hoare2, Samuel Keat1
1UK Dementia Research Institute Cardiff, School of Medicine, Cardiff University, Hadyn Ellis Building, Maindy Road, Cardiff, CF24 4HQ, UK.
Journal of neuroinflammation
|July 21, 2023
概括
阿尔茨海默病与免疫系统的变化有关. 补充基因中的特定基因变异,如CR1,C1S和CFH影响蛋白质水平,可能影响阿尔茨海默病风险.
科学领域:
- 神经免疫学 神经免疫学
- 遗传学 遗传学 是一个
- 生物标志物发现发现
背景情况:
- 阿尔茨海默病 (AD) 与免疫失调有关.
- 全基因组关联研究 (GWAS) 确定了与补充相关的基因,包括集群蛋白 (CLU) 和补充受体1 (CR1),作为AD病理学的关键参与者.
- 补充蛋白被提议作为潜在的AD生物标志物.
研究的目的:
- 为了研究AD和AD相关的补充基因变异中的血补充蛋白水平之间的关系.
- 评估补充生物标志物对AD诊断的预测效用.
- 确定遗传变异和血补充蛋白水平之间的新兴关联.
主要方法:
- 聚蛋白,C1q,C1s,CR1和H因子的血水平在早期发病的AD (EOAD),晚期发病的AD (LOAD) 和对照队列中被测量.
- 用接收器操作特征 (ROC) 分析来评估生物标志物的预测性能.
- 基因型化数据和GWAS被用来评估单核酸多态 (SNP) 对蛋白质度的影响,并确定新的关联.
主要成果:
- 与对照组相比,AD患者的血聚蛋白和C1q水平显著增加.
- 在AD患者中,血溶性CR1 (sCR1) 和H因子水平显著降低.
- 作为AD单个补充生物标志物,C1q表现出最高的预测值,与其他标志物相结合时略有改善.
- 在CR1,C1S和CFH中的SNP显著影响了相应蛋白质的血水平,而CLU的SNP没有影响群集蛋白水平.
结论:
- 在阿尔茨海默病中显而易见的补充系统失调,可能会导致其病理.
- 在CR1,C1S和CFH中与AD相关的SNP影响血蛋白水平,提供了将这些遗传变异与AD风险联系起来的潜在机制.
相关概念视频
01:27Complement System
2.4K
The complement system is a group of approximately 20 plasma proteins that strengthen the body's defenses against infections through opsonization, inflammation, and cell lysis. Opsonization involves coating pathogens with complement proteins, making them more recognizable and facilitating phagocyte engulfment. Certain complement proteins induce inflammation that attracts immune cells to the site of infection. Cell lysis involves the destruction of pathogens through the formation of a...
2.4K
01:26Alzheimer's Disease: Overview
525
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
525
01:22Alzheimer's Disease: Treatment
219
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
219